Company
Jubilant
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
5 still marketed
Novel approvals
0
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Draximage Dtpa new use Dec 26, 2017
- Drax Exametazime approved Aug 17, 2017
- Ruby-Fill approved Sep 30, 2016
- Hicon new use May 19, 2005
- Hicon approved Jan 24, 2003
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
- Draximage Mdp-10 Technetium Tc-99m Medronate · 1978
- Draximage Dtpa Technetium Tc-99m Pentetate Kit · 1989
- Hicon Sodium Iodide I-131 · 2003
- Ruby-Fill Rubidium Chloride Rb-82 · 2016
- Drax Exametazime Technetium Tc-99m Exametazime Kit · 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.